BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Placebo

First Posted Date: 2007-10-19

Last Posted Date: 2015-11-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 95

Registration Number: NCT00546715

Locations: 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸
University Of Virginia Digestive Health Center Of Excellence, Charlottesville, Virginia, United States

and more 4 locations

A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Tanespimycin
Drug: Bortezomib

First Posted Date: 2007-10-19

Last Posted Date: 2011-06-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 31

Registration Number: NCT00546780

Locations: 🇺🇸
Comprehensive Blood And Cancer Center, Bakersfield, California, United States
🇺🇸
Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇺🇸
Moores Ucsd Cancer Center, La Jolla, California, United States

and more 16 locations

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: Epofolate

First Posted Date: 2007-10-18

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 26

Registration Number: NCT00546247

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 1 locations

A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer

Phase 1

Withdrawn

Conditions: Cancer

First Posted Date: 2007-09-26

Last Posted Date: 2015-09-01

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00534807

Locations: 🇺🇸
Local Institution, Detroit, Michigan, United States

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Phase 2

Terminated

Conditions: Psoriatic Arthritis

Interventions: Drug: Placebo
Drug: Abatacept

First Posted Date: 2007-09-24

Last Posted Date: 2012-08-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 191

Registration Number: NCT00534313

Locations: 🇺🇸
Desert Medical Advances, Palm Desert, California, United States
🇺🇸
Arthritis Clinic & Carolina Bone & Joint, Pa, Charlotte, North Carolina, United States
🇺🇸
Boling Clinical Trials, Upland, California, United States

and more 17 locations

Phase IIIB Subcutaneous Missed Dose Study

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: Placebo

First Posted Date: 2007-09-24

Last Posted Date: 2015-04-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 270

Registration Number: NCT00533897

Locations: 🇺🇸
Mountain State Clinical Research, Clarksburg, West Virginia, United States
🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸
New England Research Associates, Llc, Trumbull, Connecticut, United States

and more 11 locations

Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2007-09-14

Last Posted Date: 2023-05-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 121

Registration Number: NCT00529763

Locations: 🇨🇳
Local Institution - 0004, Fuzhou, Fujian, China
🇨🇳
Local Institution - 0008, Suzhou, Jiangsu, China
🇨🇳
Local Institution, Hangzhou, Zhejiang, China

and more 1 locations

Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease

Phase 4

Completed

Conditions: Hypercholesterolemia

First Posted Date: 2007-09-14

Last Posted Date: 2011-04-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 232

Registration Number: NCT00529178

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Phase 2

Completed

Conditions: Lung Cancer
Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Ipilimumab
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2007-09-11

Last Posted Date: 2018-07-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 334

Registration Number: NCT00527735

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States
🇺🇦
Local Institution, Uzhgorod, Ukraine

and more 22 locations

DDI HV (ATV - Merck)

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Atazanavir + Raltegravir
Drug: Raltegravir
Drug: Atazanavir

First Posted Date: 2007-08-20

Last Posted Date: 2010-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT00518297

Locations: 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy